IOWA DRUG INFORMATION SERVICE
Descriptor List


ARTICLE CLASSIFICATION

            CASE REPORT/SERIES
0 CASE REPORT ADULT
2 CASE REPORT GERIATRIC
1 CASE REPORT PEDIATRIC

            CONTINUING EDUCATION
147 CE CREDIT PHARMACY

            DESIGN/ANALYSIS
167 ANNOTATED BIBLIOGRAPHY
144 CROSS-OVER
145 META-ANALYSIS
146 N-OF-ONE TRIAL
156 PRACTICE GUIDELINE
168 PRIORITY CLIN PRACT GUIDE
161 SYSTEMATIC REVIEW

            GOVERNMENT DOCUMENT
164 FDA ADVISORY COMMITTEE
155 FDA APPROVAL PACKAGE
165 FDA BLACK BOX WARNING
162 PIVOTAL STUDY

            REPORT
7 REPORT ADULT
92 REPORT GERIATRIC
91 REPORT PEDIATRIC

            REVIEW
6 REVIEW ADULT
23 REVIEW GERIATRIC
21 REVIEW PEDIATRIC

            STUDY
3 STUDY ADULT
141 STUDY CASE-CONT ADULT
143 STUDY CASE-CONT GERIATRIC
142 STUDY CASE-CONT PEDIATRIC
138 STUDY COHORT ADULT
140 STUDY COHORT GERIATRIC
139 STUDY COHORT PEDIATRIC
5 STUDY GERIATRIC
8 STUDY NON-CLINICAL
4 STUDY PEDIATRIC
135 STUDY RANDOMIZE ADULT
137 STUDY RANDOMIZE GERIATRIC
136 STUDY RANDOMIZE PEDIATRIC




OUTCOMES

            CLINICAL RESULTS
17 EFFECTIVE
18 INEFFECTIVE
19 NO CONCLUSION
20 UNEQUAL EFFECT

            ECONOMIC OUTCOMES
130 ECON COST BENEFIT
131 ECON COST EFFECTIVENESS
132 ECON COST MINIMIZATION
133 ECON COST OF ILLNESS
134 ECON COST UTILITY
129 ECON DRUG ECONOMICS

            OUTCOMES
154 OUTCOMES

            QUALITY OF LIFE
110 QUALITY OF LIFE




PHARMACEUTICS

            DRUG ANALYSIS
28 DRUG ANALYSIS PROCEDURE
27 DRUG ANALYSIS REFERENCE

            DRUG MANUFACTURE
30 MANUFACTURE PROCEDURE
29 MANUFACTURE REFERENCE

            DRUG PROPERTIES
31 IDENT ORGANOLEPTIC
32 IDENT PHYSICAL CHEMICAL

            PHARMACEUTICAL INCOMPATIBILITIES
34 INCOMPATIBILITY CHEMICAL
33 INCOMPATIBILITY PHYSICAL

            PHARMACEUTICS
109 AVAILABILITY
26 CHEMICAL FORMULA
104 CONTAMINATION
22 FORMULATION EFFICACY
35 PREPARATION
45 PRODUCT DESCRIPTION
36 STABILITY




THERAPEUTICS

            ADMINISTRATION
44 ADM ADMINISTRATION
166 ADM DRUG ELUTING DEVICE
125 ADM EAR1
124 ADM EYE1
123 ADM GASTROINTESTINAL
102 ADM GENITOURINARY
98 ADM INHALATION
160 ADM IRRIGATION
126 ADM NOSE1
64 ADM ORAL
67 ADM PARENT
111 ADM PARENT CARDIAC
96 ADM PARENT CENTRAL VENOUS
112 ADM PARENT HEPATIC
113 ADM PARENT INTRAARTERIAL
114 ADM PARENT INTRAARTICULAR
115 ADM PARENT INTRADERMAL
116 ADM PARENT INTRALESIONAL
117 ADM PARENT INTRAMUSCULAR
118 ADM PARENT INTRAOSSEOUS
119 ADM PARENT INTRAPERITONEA
120 ADM PARENT INTRAPLEURAL
66 ADM PARENT INTRAVENOUS
121 ADM PARENT LYMPH SPLEEN
100 ADM PARENT NERVOUS SYSTEM
97 ADM PARENT PORTABLE PUMP
122 ADM PARENT SUBCUTANEOUS
101 ADM RECTAL
99 ADM SUBLINGUAL BUCCAL
127 ADM THROAT1
65 ADM TOPICAL
159 ADM TRANSDERMAL

            CLINICAL
94 ANTIINFECTIVE CONC
43 DOSAGE
47 DOSIMETRY
148 DRUG RESISTANCE2
149 DRUG TOLERANCE2
41 MECHANISM OF ACTION
152 MODIFICATION EF AGE2
151 MODIFICATION EF DISEASE2
163 MODIFICATION EF SEX/GEND
42 MODIFICATION OF EFFECT
153 PATIENT HEALTH STATUS
106 PDYN CARDIOVASCULAR
107 PDYN NERVOUS
108 PDYN NUTRITION METABOLIC
105 PDYN PHARMACODYNAMICS
150 PHARMACOGENETICS2
37 PKIN ABSORPTION
95 PKIN AUC
39 PKIN BIOTRANSFORMATION
63 PKIN BLOOD CONCENTRATION
38 PKIN DISTRIBUTION
40 PKIN EXCRETION
51 PKIN EXCRETION METABOLIC
24 PKIN EXCRETION MILK
25 PKIN EXCRETION RENAL
69 PKIN FLUID TISSUE CONC
70 PKIN HALF LIFE
74 PKIN PHARMACOKINETICS

            CLINICAL INCOMPATIBILITIES
52 CONTRAINDICATION
75 DIETARY INTERACTION
50 DRUG INTERACTION
73 DRUG MODIFIED LAB VALUE

            DRUG USE
16 DRUG COMBINATION
128 DRUG UTILIZATION
158 MEDICATION ERROR
14 NEW DOSAGE REGIMEN
15 NEW ROUTE
12 NEW USE
103 PATIENT COMPLIANCE
157 PATIENT EDUCATION
13 RESEARCH USE

            SIDE EFFECTS/ADVERSE REACTIONS
46 SIDE EF ADVERSE REACTION
82 SIDE EF CARDIOVASCULAR
49 SIDE EF DEPEND REBOUND
78 SIDE EF DIGESTIVE
81 SIDE EF ENDOCRINE
48 SIDE EF FETAL EFFECT
83 SIDE EF HEMIC LYMPHATIC
90 SIDE EF IMMUNOLOGIC
77 SIDE EF MUSCULOSKELETAL
76 SIDE EF NEOPLASM CYST
84 SIDE EF NERVOUS
87 SIDE EF NUTRITION METAB
88 SIDE EF PSYCHIATRIC
79 SIDE EF RESPIRATORY
85 SIDE EF SENSE ORGANS
86 SIDE EF SKIN
89 SIDE EF SYMPTOMS PATH
93 SIDE EF TREATMENT
80 SIDE EF UROGENITAL

            TOXICOLOGY
56 TOXICOL ANTIDOTE
59 TOXICOL DIAGNOSIS
60 TOXICOL PROGNOSIS
58 TOXICOL SUPPORTIVE TREAT
55 TOXICOL SYMPTOMATOLOGY
54 TOXICOL TOXICITY
53 TOXICOL TOXICOLOGY
57 TOXICOL TREATMENT

1 See Also 68 ADM EYE EAR NOSE THROAT (1966-1993)
2 See Also 42 MODIFICATION OF EFFECT (1967-1995)


4/16/2009